Elevated EZH2 expression is consistently observed in metastatic HSPC and CRPC compared to benign and primary prostate tissue, and is associated with poor clinical outcomes, including increased recurrence risk, tumor aggressiveness, and reduced survival (48, 49). The gene discussed is EZH2; the disease is neoplasm.